Patents by Inventor Camille Locht

Camille Locht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutant Bordetella Strains and Methods of Use
    Publication number: 20230381224
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Application
    Filed: June 20, 2023
    Publication date: November 30, 2023
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 11819545
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: November 21, 2023
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Influenza vaccine, composition, and methods of use
    Publication number: 20230364217
    Abstract: The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
    Type: Application
    Filed: April 19, 2023
    Publication date: November 16, 2023
    Inventors: Sylvie Claudette Alonso, Rui Li, Vincent TK Chow, Camille Locht
  • Attenuated Bordetella Strains
    Publication number: 20220378898
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Application
    Filed: February 9, 2022
    Publication date: December 1, 2022
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • BORDETELLA STRAINS EXPRESSING SEROTYPE 3 FIMBRIAE
    Publication number: 20220362369
    Abstract: A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.
    Type: Application
    Filed: August 3, 2022
    Publication date: November 17, 2022
    Inventors: Anne-Sophie Debrie, Dominique Raze, Camille Locht
  • strains expressing serotype 3 fimbriae
    Patent number: 11446372
    Abstract: A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: September 20, 2022
    Assignees: Institut Pasteur de Lille, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
    Inventors: Anne-Sophie Debrie, Dominique Raze, Camille Locht
  • Attenuated strains
    Patent number: 11285201
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: March 29, 2022
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20210361759
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: August 2, 2021
    Publication date: November 25, 2021
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Mutant Bordetella Strains and Methods of Use
    Publication number: 20210290667
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 23, 2021
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 11110161
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: September 7, 2021
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Mutant strains and methods of use
    Patent number: 11065276
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: July 20, 2021
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Mutant Bordetella Strains and Methods of Use
    Publication number: 20200323901
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Application
    Filed: April 30, 2020
    Publication date: October 15, 2020
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • BORDETELLA STRAINS EXPRESSING SEROTYPE 3 FIMBRIAE
    Publication number: 20200297833
    Abstract: A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZElf3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.
    Type: Application
    Filed: April 14, 2020
    Publication date: September 24, 2020
    Inventors: Anne-Sophie Debrie, Dominique Raze, Camille Locht
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20200282041
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: April 3, 2020
    Publication date: September 10, 2020
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Mutant strains and methods of use
    Patent number: 10682377
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: June 16, 2020
    Assignees: Institut Pasteur de Lille, INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Attenuated Bordetella Strains
    Publication number: 20200171139
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 4, 2020
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 10653765
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: May 19, 2020
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Attenuated strains
    Patent number: 10610580
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: April 7, 2020
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology
    Publication number: 20190358309
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: August 9, 2019
    Publication date: November 28, 2019
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 10420827
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 24, 2019
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille, National University of Ireland Maynooth
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanaugh